| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Josh Mandel-Brehm is Chief Executive Officer at CAMP. Josh Mandel-Brehm's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.1M at current prices.
Net of sales, the CAMP filings show accumulation of 12,611 shares.
Josh Mandel-Brehm has 9 Form 4 filings on record from October 2024 to August 2026, across 2 companies: Chief Executive Officer at Camp4 Therapeutics (CAMP), 2024–2026; Director at ProMIS Neurosciences (PMN), 2024–2026.
The 10 reported transactions were 7 option or other derivative awards, 2 open-market purchases and 1 conversion.
Counted by filing, the open-market trades come to 2 purchases worth about $21K and no sales.
The largest open-market purchase was 6,551 shares of CAMP at an average $1.65 on August 3, 2026, about $11K.